Literature DB >> 2181334

Early aneurysm surgery and preventive therapy with intravenously administered nimodipine: a multicenter, double-blind, dose-comparison study.

J M Gilsbach1, H J Reulen, B Ljunggren, L Brandt, H von Holst, M Mokry, C von Essen, M A Conzen.   

Abstract

A European, multicenter, prospective, randomized, double-blind, dose-comparison study on preventive therapy with intravenously administered nimodipine was performed to evaluate the efficacy and tolerability of two different doses: 2 and 3 mg/h. Two hundred four patients fulfilled the criteria for enrollment in the study: surgery within 72 hours after the last subarachnoid hemorrhage, and age between 16 and 72 years. All patients who had Hunt and Hess grades of I to III were operated upon; patients who had poor Hunt and Hess grades (IV-V) were operated on according to the surgeon's choice. This treatment regimen was associated with a low incidence of delayed neurological dysfunction with no significant difference between the two dosage groups: three patients (1.5%) remained severely disabled and two (1%) moderately disabled due to vasospasm with or without additional complications. Among the patients with Hunt and Hess grades of IV or V, the long-term outcome was favorable (good-fair) for 40% and unfavorable for 60%. Among the patients with grades of I to III, the long-term outcome was favorable for 89% and unfavorable for 11%.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2181334     DOI: 10.1097/00006123-199003000-00013

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  10 in total

1.  Treatment of subarachnoid hemorrhage with human albumin: ALISAH study. Rationale and design.

Authors:  Jose I Suarez; Renee H Martin
Journal:  Neurocrit Care       Date:  2010-10       Impact factor: 3.210

2.  Dopamine D2-receptor-mediated increase in vascular and endothelial NOS activity ameliorates cerebral vasospasm after subarachnoid hemorrhage in vitro.

Authors:  Gail J Pyne-Geithman; Danielle N Caudell; Matthew Cooper; Joseph F Clark; Lori A Shutter
Journal:  Neurocrit Care       Date:  2008-09-20       Impact factor: 3.210

3.  Early neuropsychological sequelae of aneurysm surgery and subarachnoid haemorrhage.

Authors:  B O Hütter; J M Gilsbach
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

4.  The haemodynamic effect of transcranial Doppler-guided high-dose nimodipine treatment in established vasospasm after subarachnoid haemorrhage.

Authors:  S C Zygmunt; T J Delgado-Zygmunt
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

5.  Hypotensive effect of nimodipine during treatment for aneurysmal subarachnoid haemorrhage.

Authors:  F Porchet; R Chioléro; N de Tribolet
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

6.  Cognitive deficits after rupture and early repair of anterior communicating artery aneurysms.

Authors:  B O Hütter; J M Gilsbach
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

7.  Is there a difference in cognitive deficits after aneurysmal subarachnoid haemorrhage and subarachnoid haemorrhage of unknown origin?

Authors:  B O Hütter; J M Gilsbach; I Kreitschmann
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

Review 8.  Nimodipine. A review of its pharmacological properties, and therapeutic efficacy in cerebral disorders.

Authors:  A N Wadworth; D McTavish
Journal:  Drugs Aging       Date:  1992 Jul-Aug       Impact factor: 3.923

9.  Paramedian thalamic infarction caused by cisternal drain placement in open clipping for aneurysmal subarachnoid hemorrhage: Two case reports.

Authors:  Sho Tsunoda; Tomohiro Inoue; Hideaki Ono; Kazuaki Naemura; Atsuya Akabane
Journal:  Surg Neurol Int       Date:  2020-06-27

10.  Clinical trials in cardiac arrest and subarachnoid hemorrhage: lessons from the past and ideas for the future.

Authors:  Jennifer A Frontera
Journal:  Stroke Res Treat       Date:  2013-03-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.